On-Demand Cell Line Development Webinars

  1. Accelerating Biologics Drug Development With An Analytical Toolkit 5/20/2021

    Using key attributes to monitor development processes can decrease timelines, improve product quality, reduce cost, and enable implementation of key knowledge gained from an analytical toolkit.

  2. Maximizing Product Titre By Strategic Control Of Osmolality In Mammalian Cell Bioprocesses 4/30/2021

    Osmolality is a key process parameter in mammalian cell bioprocesses that affects both specific cell growth and specific cell productivity. Published data shows that hyperosmolality, used in a targeted way at particular stages of the biological production process, for certain cell types, can enhance final product yield significantly. This presentation reviews the strategies that can be used to manipulate osmolality to increase production yields of monoclonal antibodies and other recombinant proteins.

  3. Osmolality: A Predictor In Mammalian Cell Culture 4/30/2021

    In this presentation we explored the quality and significance of osmolality as a predictor for titer, glucose consumption, and growth-inhibitory by-products such as ammonium in mammalian cell culture. The measurements of different runs were used to establish correlations with osmolality and independent runs to test the predictive power of osmolality. Interestingly the osmolality is a good predictor for glucose, ammonium, and dissolved CO2 among others with a weaker power. The implementation of osmolality measurement and its application in bioprocessing is also discussed.

  4. Gene Therapy Upstream Manufacturing, Scale-up And Best Practices 3/31/2021

    Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. In this panel webinar series, hear directly from the authors of the eBook  "Insights on Successful Gene Therapy Manufacturing and Commercialization" on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

  5. Developing Scalable Upstream Workflows For Recombinant And Viral Vaccine Processes 3/25/2021

    Vaccine manufacturing is responding to challenges for increasing safety assurance and responsiveness in order to reduce the impact of pandemic such as SARS-CoV-2. Therefore, in-depth knowledge of microorganism pathogenicity leads to develop new type of vaccines such as recombinant and viral vaccines. In this presentation we will review the current main upstream vaccine production processes, considering the choice of expression system, the means by which the biological preparation is introduced into the production cell and how Pall’s flexible single-use bioreactors support rapid process development, scale-up and safeguard the quality of life-protecting vaccines and help assure compliance with cGMP.

  6. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma. 

  7. Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing 2/23/2021

    The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.

  8. The Future Of Osmolality Testing Within Cell & Gene Therapy 1/4/2021

    Learn more about our latest osmometers designed for process development while seamlessly transferring into GMP environments with advanced data management features (21 CFR Part 11) in this presentation, hosted by Kendal Studd, Applications Scientist.

  9. Optimizing Cell Culture Media Design: A Diverse Panel Reduces Uncertainty 10/20/2020

    This on-demand webinar reviews best practices for selecting the optimal media for a specific cell line’s growth using a media panel approach to reduce timelines and increase productivity.  

  10. Harnessing mRNA As A Readout To Develop Robust Biopotency Assays

    Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.